Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

1.

Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.

Huang H, Hutta DA, Hu H, DesJarlais RL, Schubert C, Petrounia IP, Chaikin MA, Manthey CL, Player MR.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2355-61. doi: 10.1016/j.bmcl.2008.02.070. Epub 2008 Mar 4.

PMID:
18342505
[PubMed - indexed for MEDLINE]
2.

Entry into a new class of protein kinase inhibitors by pseudo ring design.

Furet P, Caravatti G, Guagnano V, Lang M, Meyer T, Schoepfer J.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):897-900. doi: 10.1016/j.bmcl.2007.12.041. Epub 2008 Jan 14.

PMID:
18248988
[PubMed - indexed for MEDLINE]
3.

Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X.

J Med Chem. 2008 Mar 27;51(6):1681-94. doi: 10.1021/jm7010996. Epub 2008 Mar 6.

PMID:
18321037
[PubMed - indexed for MEDLINE]
4.

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.

Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Müller S, Daub H.

Mol Cell Proteomics. 2004 Dec;3(12):1181-93. Epub 2004 Oct 8.

PMID:
15475568
[PubMed - indexed for MEDLINE]
Free Article
5.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Claridge S, Raeppel F, Granger MC, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R, Rahil J, Beaulieu N, Nguyen H, Dupont I, Barsalou A, Beaulieu C, Chute I, Gravel S, Robert MF, Lefebvre S, Dubay M, Pascal R, Gillespie J, Jin Z, Wang J, Besterman JM, MacLeod AR, Vaisburg A.

Bioorg Med Chem Lett. 2008 May 1;18(9):2793-8. doi: 10.1016/j.bmcl.2008.04.009. Epub 2008 Apr 9.

PMID:
18434145
[PubMed - indexed for MEDLINE]
6.

Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

Lin R, Johnson SG, Connolly PJ, Wetter SK, Binnun E, Hughes TV, Murray WV, Pandey NB, Moreno-Mazza SJ, Adams M, Fuentes-Pesquera AR, Middleton SA.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2333-7. doi: 10.1016/j.bmcl.2009.02.067. Epub 2009 Feb 21.

PMID:
19286381
[PubMed - indexed for MEDLINE]
7.

Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.

Li R, Xue L, Zhu T, Jiang Q, Cui X, Yan Z, McGee D, Wang J, Gantla VR, Pickens JC, McGrath D, Chucholowski A, Morris SW, Webb TR.

J Med Chem. 2006 Feb 9;49(3):1006-15.

PMID:
16451066
[PubMed - indexed for MEDLINE]
8.

Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase.

Kempson J, Guo J, Das J, Moquin RV, Spergel SH, Watterson SH, Langevine CM, Dyckman AJ, Pattoli M, Burke JR, Yang X, Gillooly KM, McIntyre KW, Chen L, Dodd JH, McKinnon M, Barrish JC, Pitts WJ.

Bioorg Med Chem Lett. 2009 May 15;19(10):2646-9. doi: 10.1016/j.bmcl.2009.03.159. Epub 2009 Apr 5.

PMID:
19376699
[PubMed - indexed for MEDLINE]
9.

Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.

Goto T, Shiina A, Yoshino T, Mizukami K, Hirahara K, Suzuki O, Sogawa Y, Takahashi T, Mikkaichi T, Nakao N, Takahashi M, Hasegawa M, Sasaki S.

Bioorg Med Chem. 2013 Nov 15;21(22):7025-37. doi: 10.1016/j.bmc.2013.09.013. Epub 2013 Sep 19.

PMID:
24094436
[PubMed - indexed for MEDLINE]
11.

Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines.

Hafez HN, Abbas HA, El-Gazzar AR.

Acta Pharm. 2008 Dec;58(4):359-78. doi: 10.2478/v10007-008-0024-1.

PMID:
19103572
[PubMed - indexed for MEDLINE]
12.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Harmange JC, Weiss MM, Germain J, Polverino AJ, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, DiPietro L, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Martin MW, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Wang L, White RD, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7.

PMID:
18324761
[PubMed - indexed for MEDLINE]
13.

Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.

Dushin RG, Nittoli T, Ingalls C, Boschelli DH, Cole DC, Wissner A, Lee J, Yang X, Morgan P, Brennan A, Chaudhary D.

Bioorg Med Chem Lett. 2009 May 1;19(9):2461-3. doi: 10.1016/j.bmcl.2009.03.053. Epub 2009 Mar 18.

PMID:
19345579
[PubMed - indexed for MEDLINE]
14.

Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.

Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4720-3. doi: 10.1016/j.bmcl.2009.06.066. Epub 2009 Jun 21.

PMID:
19596575
[PubMed - indexed for MEDLINE]
15.

Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.

Zhao C, Tovar C, Yin X, Xu Q, Todorov IT, Vassilev LT, Chen L.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):319-23. doi: 10.1016/j.bmcl.2008.11.093. Epub 2008 Nov 27.

PMID:
19071019
[PubMed - indexed for MEDLINE]
16.

The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst JT, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1772-7. doi: 10.1016/j.bmcl.2008.02.033. Epub 2008 Feb 16.

PMID:
18325768
[PubMed - indexed for MEDLINE]
17.

Synthesis and antiproliferative activity in vitro of new 2-, 3- or 4-substituted pyrido[2',3':3,4]pyrazolo[1, 5-a]pyrimidines.

Poreba K, Wietrzyk J, Opolski A.

Acta Pol Pharm. 2006 May-Jun;63(3):189-94.

PMID:
20085223
[PubMed - indexed for MEDLINE]
Free Article
18.

Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.

Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. doi: 10.1016/j.bmcl.2009.10.085. Epub 2009 Oct 23.

PMID:
19889540
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors.

Huang H, Hutta DA, Rinker JM, Hu H, Parsons WH, Schubert C, DesJarlais RL, Crysler CS, Chaikin MA, Donatelli RR, Chen Y, Cheng D, Zhou Z, Yurkow E, Manthey CL, Player MR.

J Med Chem. 2009 Feb 26;52(4):1081-99. doi: 10.1021/jm801406h.

PMID:
19193011
[PubMed - indexed for MEDLINE]
20.

Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.

Horiuchi T, Nagata M, Kitagawa M, Akahane K, Uoto K.

Bioorg Med Chem. 2009 Dec 1;17(23):7850-60. doi: 10.1016/j.bmc.2009.10.039. Epub 2009 Oct 24.

PMID:
19889545
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk